Dienstag, 23. April 2019
Navigation öffnen

JOURNAL ONKOLOGIE – STUDIE

FIERCE-22 A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Rekrutierend

NCT-Nummer:
NCT03123055

Studienbeginn:
April 2017

Letztes Update:
16.01.2019

Wirkstoff:
B-701, Pembrolizumab

Indikation (Clinical Trials):
Carcinoma, Urinary Bladder Diseases, Urologic Diseases

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
Rainier Therapeutics

Collaborator:
-

Studienleiter

Rainier Therapeutics
Study Chair
Rainier Therapeutics

Kontakt

Studienlocations (3 von 52)

Alle anzeigen

Studien-Informationen

Detailed Description:

This is a Phase 1b/2 multi-center, open-label study to determine the safety, tolerability, and efficacy of B-701 (vofatamab) plus pembrolizumab in the treatment of subjects with locally advanced or metastatic UCC, who have progressed following platinum-based chemotherapy and who have not received prior immune checkpoint inhibitor or FGFR inhibitor-targeted therapy. The study consists of 2 parts: a Phase 1b lead-in phase enrolling 6 to 18 subjects and a Phase 2 dose expansion phase enrolling up to a total of 74 subjects.

Subjects who discontinue B-701 (vofatamab) may continue on study and receive pembrolizumab alone until disease progression, death, withdrawal of patient consent, or study termination. Subjects who discontinue pembrolizumab may continue on study and receive B-701 (vofatamab) alone until disease progression, death, withdrawal of patient consent, or study termination.

Ein-/Ausschlusskriterien

Key Inclusion Criteria:

1. Have locally advanced (on TNM staging: T4b and any N, or any T and N2-3) or metastatic transitional cell carcinoma of the urothelium, including of the urinary bladder, urethra, ureter, and/or renal pelvis. The diagnosis must be histologically or cytologically confirmed.

2. Have progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

3. Have available archival tumor or be willing to undergo diagnostic biopsy at screening. Sample must be of suitable quality and quantity to satisfy group assignment and biomarker endpoints.

4. Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1.

Key Exclusion Criteria:

1. Participants with a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on the Screening chest CT scan.

2. Prior therapy with an anti-programmed cell death 1 (PD-1) or anti-PD-Ligand 1 agent, or with an agent directed to another co-inhibitory T-cell receptor or FGFR inhibitor.

3. Patients with autoimmune disease or medical conditions that required systemic corticosteroids (> 10 mg/day prednisone or its equivalent) or other immunosuppressive medications or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of study treatment. Note: Replacement therapy (e.g. physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

4. Primary central nervous system (CNS) malignancy or CNS metastases.

5. History of clinically significant coagulation or platelet disorder in the past 12 months.

Studien-Rationale

Primary outcome:

1. Initial safety and determination of recommended Phase 2 dose according to dose-limiting Toxicity (Time Frame - 1 year):
DLTs within a period of 35 days will be analyzed reviewing the aggregate of adverse events (AEs) and serious adverse events (SAEs) by the B-701 program Safety Oversight Committee and will result in a recommended Phase 2 dose.

2. Safety and tolerability of B-701 (vofatamab) plus pembrolizumab (Time Frame - 2.5 years):
Evaluate the safety and tolerability of B-701 (vofatamab) plus pembrolizumab in subjects with UCC as assessed by number of subjects experiencing adverse events (AEs and SAEs), physical examination findings, laboratory test results, and vital signs over time.

3. Efficacy of B-701 (vofatamab) plus pembrolizumab measured by ORR (Time Frame - 2 years):
Evaluate the efficacy of B-701 (vofatamab) plus pembrolizumab in subjects with UCC as measured by objective response rate (ORR) by RECIST 1.1. ORR is defined as the percentage of subjects who have baseline measurable disease and who achieve a best response of either complete response (CR) or partial response (PR).

Secondary outcome:

1. Assessment of changes in biomarkers induced by B-701 (vofatamab) (Time Frame - 2.5 years):
Whole blood (PBMCs), serum, and plasma samples for biomarker analyses will be obtained prior to infusion of B-701 at pre-defined visit days. The effects of B-701 on the downstream signaling of the FGFR3 pathway, tumor sub-type and on the immune surveillance of UCC tumors will be monitored using techniques that include gene expression profiling (such as whole transcriptome RNAseq), sequencing of T-cell receptors, and immunohistochemistry.

2. Efficacy of B-701 (vofatamab) in combination with pembrolizumab as measured by DOR (Time Frame - 2 years):
Evaluate the efficacy of B-701 (vofatamab) in combination with pembrolizumab in the treatment of subjects with UCC as measured by duration of objective response (DOR), defined as the time from first occurrence of a documented, objective response until the time of relapse or death from any cause (RECIST 1.1).

3. Efficacy of B-701 (vofatamab) in combination with pembrolizumab as measured by DCR (Time Frame - 2 years):
Evaluate the efficacy of B-701 in combination with pembrolizumab in the treatment of subjects with UCC as measured by disease control rate (DCR), defined as the percentage of subjects who achieve either complete response (CR) or partial response (PR) or stable disease (SD) according to RECIST 1.1.

4. Efficacy of B-701 (vofatamab) in combination with pembrolizumab as measured by PFS (Time Frame - 2 years):
Evaluate the efficacy of B-701 (vofatamab) in combination with pembrolizumab in the treatment of subjects with UCC as measured by progression-free survival (PFS), defined as the time from a first study treatment dose to first occurrence of disease progression (per RECIST 1.1) or death from any cause, whichever occurs first.

5. Efficacy of B-701 (vofatamab) in combination with pembrolizumab as measured by OS (Time Frame - 2.5 years):
Evaluate the efficacy of B-701 (vofatamab) in combination with pembrolizumab in the treatment of subjects with UCC as measured by overall survival (OS), defined as the time from first study drug administration to death from any cause (RECIST 1.1)

6. Change in subject reported quality of life (Time Frame - 2 years):
Evaluate the efficacy of B-701 (vofatamab) in combination with pembrolizumab in the treatment of subjects with UCC as measured by the change over time in subject reported quality of life as measured by the European Organization for Research and Treatment Quality of Life Questionnaire (EORTC QLQ-C30).

Studien-Arme

  • Experimental: B-701 (vofatamab)
    B-701 (vofatamab, 25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.
  • Experimental: B-701 (vofatamab) plus pembrolizumab
    B-701 (vofatamab, 25 mg/kg [or the recommended Phase 2 dose if different than 25 mg/kg]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.

Geprüfte Regime

  • B-701 (MFGR1877S / Vofatamab / ):
    B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
  • Pembrolizumab (Keytruda):
    Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Studie zu Online-Programm zur Stressreduktion ausgezeichnet

Studie zu Online-Programm zur Stressreduktion ausgezeichnet
© Andrey Popov / fotolia.com

Der Reinhold-Schwarz-Förderpreis für Psychoonkologie 2018 wurde an die Psychologin Astrid Grossert-Leugger, Basel, verliehen. Die Preisträgerin erhielt die mit 2.500 € dotierte Auszeichnung für ihre Arbeit zum Thema „Web-Based Stress Management for Newly Diagnosed Patients with Cancer (STREAM): A Randomized, Wait‐List Controlled Intervention Study“. Die Preisverleihung erfolgte auf der 17. Jahrestagung der Arbeitsgemeinschaft für Psychoonkologie...

Primäre Studienendpunkte: Gesamtüberleben oder progressionsfreies Überleben - gibt es einen Goldstandard?

Anerkanntes Ziel einer Therapie von Krebspatienten ist die Verbesserung des Überlebens und der Lebensqualität. Historisch gesehen gilt die Gesamtüberlebenszeit (OS = overall survival) als der wichtigste primäre klinische Endpunkt einer Studie. Doch das Gesamtüberleben als primärer Studienendpunkt unterliegt nicht zuletzt aufgrund der Fortschritte, die in letzten Jahren in der Krebstherapie erzielt wurden, gewissen Einschränkungen. So können...

Bayern gegen Darmkrebs: Das Modellprojekt „Sprich drüber!“ will junge Menschen im Freistaat vor einer Erkrankung bewahren.

Bayern gegen Darmkrebs: Das Modellprojekt „Sprich drüber!“ will junge Menschen im Freistaat vor einer Erkrankung bewahren.
FARKOR: Werbe-Anzeige Frau / © Felix Burda Stiftung

Auf Initiative der Felix Burda Stiftung haben sich die bayerischen Krankenkassen und die Kassenärztliche Vereinigung Bayerns (KVB) zum Modellprojekt „Sprich drüber!“ zusammengeschlossen. Ziel des Projekts ist es, ein vorhandenes familiäres Darmkrebsrisiko bei Versicherten im Alter von 25 bis 49 Jahren möglichst so früh zu identifizieren, dass diese vor einer Darmkrebserkrankung bewahrt werden können. Jede Bayerin und jeder Bayer in dieser...